HK1215701A1 - 苯達莫司汀衍生物及其使用方法 - Google Patents

苯達莫司汀衍生物及其使用方法 Download PDF

Info

Publication number
HK1215701A1
HK1215701A1 HK16100090.1A HK16100090A HK1215701A1 HK 1215701 A1 HK1215701 A1 HK 1215701A1 HK 16100090 A HK16100090 A HK 16100090A HK 1215701 A1 HK1215701 A1 HK 1215701A1
Authority
HK
Hong Kong
Prior art keywords
compound
cancer
alkyl group
bendamustine
formula
Prior art date
Application number
HK16100090.1A
Other languages
English (en)
Chinese (zh)
Inventor
羅格
P 巴卡列 罗格
巴卡列
D 布朗 彼得
彼得
陈建
布朗
S 查格尔 安东尼
陳建
Y 拉贝尔 拉切尔
安東尼
E 麦凯恩 罗伯特
查格爾
R 帕特尔 皮约什
拉切爾
C 勒姆麦尔 雷内
拉貝爾
羅伯特
麥凱恩
皮約什
帕特爾
雷內
勒姆麥爾
Original Assignee
易格尼塔公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 易格尼塔公司 filed Critical 易格尼塔公司
Publication of HK1215701A1 publication Critical patent/HK1215701A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/16—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Saccharide Compounds (AREA)
HK16100090.1A 2012-11-12 2013-11-12 苯達莫司汀衍生物及其使用方法 HK1215701A1 (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261725213P 2012-11-12 2012-11-12
US201261725213P 2012-11-12
US201361776951P 2013-03-12 2013-03-12
US201361776951P 2013-03-12
PCT/US2013/069550 WO2014075035A1 (en) 2012-11-12 2013-11-12 Bendamustine derivatives and methods of using same

Publications (1)

Publication Number Publication Date
HK1215701A1 true HK1215701A1 (zh) 2016-09-09

Family

ID=49667594

Family Applications (2)

Application Number Title Priority Date Filing Date
HK16100090.1A HK1215701A1 (zh) 2012-11-12 2013-11-12 苯達莫司汀衍生物及其使用方法
HK16100891.2A HK1212977A1 (zh) 2012-11-12 2013-11-12 苯達莫司汀衍生物及其使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
HK16100891.2A HK1212977A1 (zh) 2012-11-12 2013-11-12 苯達莫司汀衍生物及其使用方法

Country Status (17)

Country Link
US (7) US9452988B2 (OSRAM)
EP (1) EP2917183A1 (OSRAM)
JP (1) JP6262246B2 (OSRAM)
KR (1) KR20150086308A (OSRAM)
AR (1) AR093457A1 (OSRAM)
AU (1) AU2013342015B2 (OSRAM)
BR (1) BR112015010501A2 (OSRAM)
CA (1) CA2890462A1 (OSRAM)
CL (1) CL2015001246A1 (OSRAM)
EA (1) EA029706B1 (OSRAM)
HK (2) HK1215701A1 (OSRAM)
IL (1) IL238662A (OSRAM)
MX (1) MX2015005805A (OSRAM)
PH (1) PH12015501024A1 (OSRAM)
SG (1) SG11201503560TA (OSRAM)
TW (1) TWI598341B (OSRAM)
WO (1) WO2014075035A1 (OSRAM)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105693720B (zh) 2010-05-20 2019-01-18 阵列生物制药公司 作为trk激酶抑制剂的大环化合物
MX2015005805A (es) * 2012-11-12 2016-04-15 Ignyta Inc Derivados de bendamustina y métodos para utilizarlos.
CA2904143A1 (en) * 2013-03-12 2014-10-09 Cephalon, Inc. Nanoparticulate and macroparticulate formulations
EP3322706B1 (en) 2015-07-16 2020-11-11 Array Biopharma, Inc. Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors
WO2018013783A1 (en) * 2016-07-13 2018-01-18 Cephalon, Inc. Pharmaceutical prodrugs and methods of their preparation and use
TWI704148B (zh) 2016-10-10 2020-09-11 美商亞雷生物製藥股份有限公司 作為ｒｅｔ激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物
JOP20190077A1 (ar) 2016-10-10 2019-04-09 Array Biopharma Inc مركبات بيرازولو [1، 5-a]بيريدين بها استبدال كمثبطات كيناز ret
CN110267960B (zh) 2017-01-18 2022-04-26 阿雷生物药品公司 作为RET激酶抑制剂的取代的吡唑并[1,5-a]吡嗪化合物
WO2018136663A1 (en) 2017-01-18 2018-07-26 Array Biopharma, Inc. Ret inhibitors
JOP20190213A1 (ar) 2017-03-16 2019-09-16 Array Biopharma Inc مركبات حلقية ضخمة كمثبطات لكيناز ros1
TWI791053B (zh) 2017-10-10 2023-02-01 美商亞雷生物製藥股份有限公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物
TWI812649B (zh) 2017-10-10 2023-08-21 美商絡速藥業公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物
TW201938169A (zh) 2018-01-18 2019-10-01 美商亞雷生物製藥股份有限公司 作為RET激酶抑制劑之經取代吡唑并[3,4-d]嘧啶化合物
WO2019143994A1 (en) 2018-01-18 2019-07-25 Array Biopharma Inc. Substituted pyrazolyl[4,3-c]pyridinecompounds as ret kinase inhibitors
CN111971286B (zh) 2018-01-18 2023-04-14 阿雷生物药品公司 作为RET激酶抑制剂的取代的吡咯并[2,3-d]嘧啶化合物
KR102653681B1 (ko) 2018-07-31 2024-04-03 록쏘 온콜로지, 인코포레이티드 (s)-5-아미노-3-(4-((5-플루오로-2-메톡시벤즈아미도)메틸)페닐)-1-(1,1,1-트리플루오로프로판-2-일)-1h-피라졸-4-카르복스아미드의분무-건조된 분산물 및 제제
ES2922314T3 (es) 2018-09-10 2022-09-13 Array Biopharma Inc Compuestos heterocíclicos condensados como inhibidores de cinasa RET

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5681964A (en) * 1990-10-23 1997-10-28 University Of Kentucky Research Foundation Permeable, non-irritating prodrugs of nonsteroidal and steroidal agents
US5834025A (en) 1995-09-29 1998-11-10 Nanosystems L.L.C. Reduction of intravenously administered nanoparticulate-formulation-induced adverse physiological reactions
US7089218B1 (en) 2004-01-06 2006-08-08 Neuric Technologies, Llc Method for inclusion of psychological temperament in an electronic emulation of the human brain
US8853260B2 (en) 1997-06-27 2014-10-07 Abraxis Bioscience, Llc Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
WO2002043663A2 (en) 2000-12-01 2002-06-06 Enzon, Inc. Tetrapartate prodrugs
WO2003086369A2 (en) * 2002-04-05 2003-10-23 Valorisation-Recherche, Societe En Commandite Stealthy polymeric biodegradable nanospheres and uses thereof
EP2359859A1 (en) 2002-12-09 2011-08-24 Abraxis BioScience, LLC Compositions comprising albumin nanoparticles and methods of delivery of pharmacological agents
US8436190B2 (en) 2005-01-14 2013-05-07 Cephalon, Inc. Bendamustine pharmaceutical compositions
CA2598239C (en) 2005-02-18 2019-10-29 Abraxis Bioscience, Inc. Nanoparticulate formulations of taxanes and carrier proteins for use in combination chemotherapy
DE102005062440B4 (de) * 2005-12-27 2011-02-24 Lts Lohmann Therapie-Systeme Ag Proteinbasiertes Trägersystem zur Resistenzüberwindung von Tumorzellen
EP2222278B1 (en) 2007-11-28 2015-04-08 Celator Pharmaceuticals, Inc. Improved taxane delivery system
AR072777A1 (es) 2008-03-26 2010-09-22 Cephalon Inc Formas solidas de clorhidrato de bendamustina
JP5670335B2 (ja) * 2008-09-25 2015-02-18 セファロン、インク． ベンダムスチン液体製剤
WO2010037142A1 (en) * 2008-09-29 2010-04-01 The Corporation Of Mercer University Nanospheres encapsulating bioactive material and method for formulation of nanospheres
JP5773874B2 (ja) * 2008-10-08 2015-09-02 セファロン、インク． ベンダムスチンの調製方法
CN105363037B (zh) * 2008-12-03 2019-02-05 安斯泰来德国有限公司 苯达莫司汀的口服剂型
BR112012030654B1 (pt) 2010-06-02 2021-11-09 Astellas Deutschland Gmbh Composição farmacêutica para administração oral compreendendo bendamustina ou um sal farmaceuticamente aceitável da mesma, como um ingrediente ativo, e um excipiente farmaceuticamente aceitável
TWI455722B (zh) 2010-06-04 2014-10-11 Pfizer Vaccines Llc 用於預防或治療菸鹼成癮之共軛體
CN101966158A (zh) 2010-09-28 2011-02-09 上海丽思化工科技有限公司 一种注射用盐酸苯达莫司汀冻干粉针剂及其制备方法
EP2635558A4 (en) 2010-11-01 2014-08-06 Shilpa Medicare Ltd PROCESS FOR PREPARING BENDAMUSTINE HYDROCHLORIDE MONOHYDRATE
DE102010055499A1 (de) 2010-12-22 2011-06-16 W.C. Heraeus Gmbh Prozess zur Herstellung von Bendamustinalkylester, Bendarmustin sowie Derivaten davon
PT2707030T (pt) 2011-05-09 2020-05-22 Mayo Found Medical Education & Res Tratamentos de cancro
US9308276B2 (en) 2011-05-17 2016-04-12 University Of South Alabama Combination therapy for treatment of cancer
ES2613838T3 (es) 2011-09-26 2017-05-26 Fresenius Kabi Oncology Ltd Un procedimiento mejorado para la preparación de hidrocloruro de bendamustina
PT2656843E (pt) 2012-04-26 2015-04-14 Helmut Schickaneder Ésteres de bendamustina e compostos relacionados e a sua utilização médica
US10526290B2 (en) 2012-06-19 2020-01-07 Synbias Pharma Ag Bendamustine derivatives and related compounds, and medical use thereof in cancer therapy
JP2015525799A (ja) 2012-08-10 2015-09-07 ユニバーシティ・オブ・ノース・テキサス・ヘルス・サイエンス・センターＵｎｉｖｅｒｓｉｔｙ ｏｆ Ｎｏｒｔｈ Ｔｅｘａｓ Ｈｅａｌｔｈ Ｓｃｉｅｎｃｅ Ｃｅｎｔｅｒ ターゲティングポリアミノ酸および脂肪酸のコンジュゲートを含む薬物送達ビークル
MX2015005805A (es) * 2012-11-12 2016-04-15 Ignyta Inc Derivados de bendamustina y métodos para utilizarlos.

Also Published As

Publication number Publication date
AU2013342015A1 (en) 2015-05-28
US9630926B2 (en) 2017-04-25
US20170182008A1 (en) 2017-06-29
EA201590925A1 (ru) 2015-09-30
WO2014075035A1 (en) 2014-05-15
US20180147186A1 (en) 2018-05-31
CN105051016A (zh) 2015-11-11
AR093457A1 (es) 2015-06-10
JP2015536996A (ja) 2015-12-24
CL2015001246A1 (es) 2016-01-15
EA029706B1 (ru) 2018-05-31
PH12015501024A1 (en) 2015-07-27
HK1212977A1 (zh) 2016-06-24
TWI598341B (zh) 2017-09-11
US9452988B2 (en) 2016-09-27
EP2917183A1 (en) 2015-09-16
SG11201503560TA (en) 2015-06-29
AU2013342015B2 (en) 2016-11-24
BR112015010501A2 (pt) 2017-07-11
IL238662A0 (en) 2015-06-30
TW201439069A (zh) 2014-10-16
US20160289198A1 (en) 2016-10-06
KR20150086308A (ko) 2015-07-27
JP6262246B2 (ja) 2018-01-17
US9913827B2 (en) 2018-03-13
MX2015005805A (es) 2016-04-15
IL238662A (en) 2017-08-31
US9150517B2 (en) 2015-10-06
US20150274675A1 (en) 2015-10-01
CA2890462A1 (en) 2014-05-15
US9149464B2 (en) 2015-10-06
US20150246023A1 (en) 2015-09-03
US20150232427A1 (en) 2015-08-20
US20160016912A1 (en) 2016-01-21

Similar Documents

Publication Publication Date Title
HK1215701A1 (zh) 苯達莫司汀衍生物及其使用方法
ES2912739T3 (es) Derivados de aminoácidos funcionalizados en el extremo N-terminal capaces de formar microesferas de encapsulación de fármacos
JP2021509138A (ja) 両親媒性ブロック共重合体及びその調製方法とナノミセル薬物キャリヤーシステム
CA2643826A1 (en) Compositions and methods for transport of molecules with enhanced release properties across biological barriers
US20210361777A1 (en) Pharmaceutical prodrugs and methods of their preparation and use
RU2721949C2 (ru) Модифицированные цитотоксины и их терапевтическое применение
CN117964514B (zh) 可电离脂质化合物及其制备方法和应用
US20190374468A1 (en) Liposomal Formulations for Allosteric AKT Inhibitors
CN109922834B (zh) 用于治疗癌症的卟啉化合物和组合物
CA3232690A1 (en) Multi-motif dendrons and their supramolecular structures and uses thereof
CN113166189A (zh) 吉西他滨两亲性前体药物
CN105051016B (zh) 苯达莫司汀衍生物及其使用方法
TW201807025A (zh) 主動標靶型高分子衍生物、包含該高分子衍生物之組合物、及其等之用途
CN121175037A (zh) 用于制备包封试剂的脂质纳米颗粒的化合物、包含所述化合物的纳米颗粒组合物及其相关方法
CN117126095A (zh) 含单一分子量聚乙二醇链段的可释放性功能化合物、包含其的纳米粒子及制备方法
HK40008068B (zh) 用於治疗癌症的卟啉化合物和组合物